1. Abel S, Russell D, Ridgway C, Muirhead G (2005a). Overview of the drug-drug Antimicrobial Agents and Chemotherapy, 17-20 September 2000, Toronto, interaction data for maraviroc. Presented at the6th International Workshop Canada. on Clinical Pharmacology of HIV Therapy, 28-30April 2005, Quebec, Bittner B, Riek M, Holmes B, Grange S(2005). Saquinavir 500-mg film-coated Canada. tablets demonstrate bioequivalence to saquinavir 200-mg hard capsules
2. Abel S, Taylor-Worth R, Ridgway C (2005b). Effect of boosted tipranavir when boosted with twice daily ritonavir in healthy volunteers. Antivir Ther on the pharmacokinetics of maraviroc (UK 427,857) in healthy volunteers. 10: 803. Presented at the10th European AIDS Conference, 17-20 November, Bochet MV, Jacquiaud C, Valantin MA et al. (1998). Renal insufficiency Dublin, Ireland. induced by ritonavir in HIV-infected patients. Am J Med 105: 457.
3. Agarwala S, Russo R, Mummaneni V (2002). Steady-state Boffito M, Winston A, Jackson A et al. (2007). Pharmacokinetics and pharmacokinetic interaction study of atazanavir with ritonavir in antiretroviral response to darunavir/ritonavir and etravirine combination in healthy subjects. Presented at the42nd Interscience Conference on patients with high-level viral resistance. AIDS 21: 1449. Antimicrobial Agents and Chemotherapy, 27-30 September 2002, San Boyd M, Aarnouste R, Ruxrungtham K et al. (2003). Pharmacokinetics of Diego, CA. indinavir/ritonavir (800 mg/100 mg) in combination with efavirenz (600 mg)